Frontlight ResearchEarly access
CompletedPhase 3
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
Key facts
- Who runs it
- University of Oxford
- Where
- Burkina Faso, Congo - Kinshasa, Gambia, Guinea, Niger, Nigeria, Rwanda, and Tanzania8 sites in 8 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 2,583 people enrolled
- Started
- 1 Sept 2020
- Ended
- 15 Mar 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Artemether-lumefantrine+ Amodiaquine (AL+AQ)
- Artemether-lumefantrine + placebo (AL+PBO)
- Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Artesunate-mefloquine+placebo (AS-MQ+PBO)
- Record updated
- 18 November 2025
Who can take part
- Age
- 6 months to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (21)Hide the full registry criteria
Who can take part
- Male or female, aged ≥6 months to <12 years (For Gambia, Rwanda sites only: ≥6 months)
- Ability to take oral medication
- Acute uncomplicated P. falciparum monoinfection
- Asexual P. falciparum parasitaemia: 1,000/µL to ≤10% parasitaemia, determined on a peripheral blood film (At Gambia, Rwanda sites only: For subjects ≥12 years - 1000/µL to 200,000/µL)
- Fever defined as ≥ 37.5°C tympanic temperature or a history of fever within the last 24 hours
- Written informed consent by the subject or by parent/guardian in case of children lower than the age of consent and assent if required (per local regulations)
- Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study
Who cannot take part
- Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days
- Previous splenectomy
- Enrolment in DeTACT in the previous 3 months
- Participation in another interventional study in the previous 3 months
- Acute illness other than malaria requiring systemic treatment
- Known HIV infection
- Known tuberculosis infection
- History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy
- Haematocrit <15% at screening (For Gambia, Rwanda sites only: For subjects ≥12 years - Haematocrit <20% at screening)
- Signs of severe malaria (adapted from WHO criteria)
- Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician
- In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 14 days
- Severe acute malnutrition (in Niger only - only those patients with Severe Acute Malnutrition and complications requiring inpatient nutritional treatment will be excluded)
- For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant, trying to get pregnant or are lactating)
Where is this trial?
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the ACTs artemether-lumefantrine+placebo (AL+PBO), artesunate-mefloquine+placebo (ASMQ+PBO) (with single-low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria to assess and compare their efficacy, safety, tolerability.
The 4 groups in the trial
- Artemether-lumefantrine+amodiaquine (AL+AQ)Treatment being tested
Triple ACTs
- artemether-lumefantrine+placebo (AL+PBO)Existing treatment, for comparison
ACTs
- Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)Treatment being tested
Triple ACTs
- Artesunate-mefloquine+placebo (AS-MQ+PBO)Existing treatment, for comparison
ACTs
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa
- Record updated
- 18 November 2025